Patent application number | Description | Published |
20130288324 | CYTOCHROME P450 OXYGENASES - Nucleic acids encoding cytochrome P450 variants are provided. The cytochrome P450 variants of have a higher alkane-oxidation capability, alkene-oxidation capability, and/or a higher organic-solvent resistance than the corresponding wild-type or parent cytochrome P450 enzyme. A preferred wild-type cytochrome P450 is cytochrome P450 BM-3. Preferred cytochrome P450 variants include those having an improved capability to hydroxylate alkanes and epoxidate alkenes comprising less than 8 carbons, and have amino acid substitutions corresponding to V78A, H236Q, and E252G of cytochrome P450 BM-3. Preferred cytochrome P450 variants also include those having an improved hydroxylation activity in solutions comprising co-solvents such as DMSO and THF, and have amino acid substitutions corresponding to T235A, R471A, E494K, and S1024E of cytochrome P450 BM-3. | 10-31-2013 |
20140322792 | CYTOCHROME P450 OXYGENASES - Nucleic acids encoding cytochrome P450 variants are provided. The cytochrome P450 variants of have a higher alkane-oxidation capability, alkene-oxidation capability, and/or a higher organic-solvent resistance than the corresponding wild-type or parent cytochrome P450 enzyme. A preferred wild-type cytochrome P450 is cytochrome P450 BM-3. Preferred cytochrome P450 variants include those having an improved capability to hydroxylate alkanes and epoxidate alkenes comprising less than 8 carbons, and have amino acid substitutions corresponding to V78A, H236Q, and E252G of cytochrome P450 BM-3. Preferred cytochrome P450 variants also include those having an improved hydroxylation activity in solutions comprising co-solvents such as DMSO and THF, and have amino acid substitutions corresponding to T235A, R471A, E494K, and S1024E of cytochrome P450 BM-3. | 10-30-2014 |
Patent application number | Description | Published |
20080293928 | Cytochrom P450 oxygenases - Nucleic acids encoding cytochrome P450 variants are provided. The cytochrome P450 variants of have a higher alkane-oxidation capability, alkene-oxidation capability, and/or a higher organic-solvent resistance than the corresponding wild-type or parent cytochrome P450 enzyme. A preferred wild-type cytochrome P450 is cytochrome P450 BM-3. Preferred cytochrome P450 variants include those having an improved capability to hydroxylate alkanes and epoxidate alkenes comprising less than 8 carbons, and have amino acid substitutions corresponding to V78A, H236Q, and E252G of cytochrome P450 BM-3. Preferred cytochrome P450 variants also include those having an improved hydroxylation activity in solutions comprising co-solvents such as DMSO and THF, and have amino acid substitutions corresponding to T235A, R471A, E494K, and S1024E of cytochrome P450 BM-3. | 11-27-2008 |
20100248327 | CYTOCHROME P450 OXYGENASES - Nucleic acids encoding cytochrome P450 variants are provided. The cytochrome P450 variants of have a higher alkane-oxidation capability, alkene-oxidation capability, and/or a higher organic-solvent resistance than the corresponding wild-type or parent cytochrome P450 enzyme. A preferred wild-type cytochrome P450 is cytochrome P450 BM-3. Preferred cytochrome P450 variants include those having an improved capability to hydroxylate alkanes and epoxidate alkenes comprising less than 8 carbons, and have amino acid substitutions corresponding to V78A, H236Q, and E252G of cytochrome P450 BM-3. Preferred cytochrome P450 variants also include those having an improved hydroxylation activity in solutions comprising co-solvents such as DMSO and THF, and have amino acid substitutions corresponding to T235A, R471A, E494K, and S1024E of cytochrome P450 BM-3. | 09-30-2010 |
20120184015 | CYTOCHROME P450 OXYGENASES - Nucleic acids encoding cytochrome P450 variants are provided. The cytochrome P450 variants of have a higher alkane-oxidation capability, alkene-oxidation capability, and/or a higher organic-solvent resistance than the corresponding wild-type or parent cytochrome P450 enzyme. A preferred wild-type cytochrome P450 is cytochrome P450 BM-3. Preferred cytochrome P450 variants include those having an improved capability to hydroxylate alkanes and epoxidate alkenes comprising less than 8 carbons, and have amino acid substitutions corresponding to V78A, H236Q, and E252G of cytochrome P450 BM-3. Preferred cytochrome P450 variants also include those having an improved hydroxylation activity in solutions comprising co-solvents such as DMSO and THF, and have amino acid substitutions corresponding to T235A, R471A, E494K, and S1024E of cytochrome P450 BM-3. | 07-19-2012 |
Patent application number | Description | Published |
20090211908 | Devices and methods for detecting and quantitating nucleic acids using size-separation of amplicons - Devices and methods are described for detecting and quantifying nucleic acids using a sealed system that minimizes contamination. In particular, provided herein are devices for and methods using nucleic acid amplification that permit multiple sampling of an amplification reaction mixture and quantitation and identification of amplicons during the course of an amplification reaction. Methods involving the transfer of samples from an amplification reaction mixture into a separation network, separation of nucleic acids based on size, and identification and quantitation of nucleic acids are disclosed. | 08-27-2009 |
20100112588 | METHODS FOR SANGER SEQUENCING USING PARTICLE ASSOCIATED CLONAL AMPLICONS AND HIGHLY PARALLEL ELECTROPHORETIC SIZE-BASED SEPARATION - Methods for highly parallel Sanger sequencing are discussed. In particular, provided herein are methods using particles to clonally amplify templates and to introduce the amplified nucleic acids into many parallel channels with a single template per channel. Once in the channels, the nucleic acids are separated by size using electrophoresis to produce long read length sequencing information. Methods involving optical detection of the size-separated nucleic acids and analysis of the resulting electropherograms to yield the sequences are disclosed. | 05-06-2010 |
20110059864 | Sequence Determination By Use Of Opposing Forces - The present teachings relate to systems, methods, and the like, for analyzing biological polymers, by use of opposing forces. Among other things, the present teachings can be used to determine sequence information, such as in genetic sequencing and genotyping applications. Various embodiments are described for efficient, high throughput sequencing of nucleic-acid molecules, such as DNA. Various embodiments are described wherein nucleic-acid sequence information is determined without the need or use of extrinsic labels. As well various embodiments of methods, systems, and the like, are described, which can provide long and accurate read lengths for low-cost nucleic acid sequencing. | 03-10-2011 |
20120220486 | METHODS AND APPARATUS FOR BINDING ASSAYS - The present teachings relate to methods, systems, and apparatus for low cost label-free assay detection. The present teachings, in a variety of embodiments, employ opposing forces to detect signals which depend on the number of charges on and/or the size of a particle. The particle, which can be subjected to opposing forces, can have specific capture probes at its surface. As analytes of interest are captured by the particle, the number of charges on the particle surface and/or the size of the particle is changed. A particle parameter or kinematic property such as the position, velocity, acceleration or force of/on the particle can be measured, and results obtained relating, for example, to the present, absence, quantity, and such, of one or more analytes of interest. Various embodiments are described for efficient, high throughput assays of samples potentially including one or more analytes of interest, such as bioanalytes. As well, various embodiments are described wherein binding assays can be carried out without the need or use of extrinsic labels. A number of embodiments provide, for example, methods, systems, and apparatus for detecting analytes (such as nucleic acids, proteins, cells and other entities, particulates, and the like) in one or more samples. Also described are: detection of a single copy of a target biomolecule, such as DNA, captured onto a trapped (e.g., tethered) bead; protocols for fabricating encoded bead arrays for multiplex assays; and methods, systems and apparatus for efficient and specific capture of pathogen biomolecular markers onto bead-bound capture probes, as well as detection and measurement of such capture events. | 08-30-2012 |
Patent application number | Description | Published |
20080277356 | Microfluidic Device with a Filter - A microfluidic device with a filter includes a substrate; a flowpath including a well formed in the substrate in fluid communication with a channel formed in the substrate; and a filter disposed across the flowpath. | 11-13-2008 |
20090118139 | Microfluidic method and system for enzyme inhibition activity screening - Methods for screening a compound for enzyme inhibition activity include providing at least one sample mixture to a microfluidic device, applying vacuum pressure to the sample mixture, flowing the sample mixture along a microchannel of the microfluidic device, separating at least two components of the sample mixture based upon a net charge difference between the product and at least one other material to produce separated material, detecting at least one of the separated materials, and determining enzyme inhibition activity based on the detection of the separated material. Kits for screening a compound for enzyme inhibition activity include a first multiwell plate having a specific plurality of enzymes disposed within a first plurality of wells and a second multiwell plate having a plurality of enzyme substrates disposed with a second plurality of wells, a phosphate source and a cofactor disposed within each well of the second plate. | 05-07-2009 |
20090186344 | DEVICES AND METHODS FOR DETECTING AND QUANTITATING NUCLEIC ACIDS USING SIZE SEPARATION OF AMPLICONS - Devices and methods are described for detecting and quantifying nucleic acids using a sealed system that minimizes contamination. In particular, provided herein are devices for and methods using nucleic acid amplification that permit multiple sampling of an amplification reaction mixture and quantitation and identification of amplicons during the course of an amplification reaction. Methods involving the transfer of samples from an amplification reaction mixture into a separation network, separation of nucleic acids based on size, and identification and quantitation of nucleic acids are disclosed. | 07-23-2009 |
20120009098 | MICROFLUIDIC DEVICE WITH A FILTER - A microfluidic device with a filter includes a substrate; a flowpath including a well formed in the substrate in fluid communication with a channel formed in the substrate; and a filter disposed across the flowpath and associated with the channel. | 01-12-2012 |
Patent application number | Description | Published |
20120029445 | POSTERIOR SEGMENT DRUG DELIVERY - A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side. | 02-02-2012 |
20120029470 | POSTERIOR SEGMENT DRUG DELIVERY - A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side. | 02-02-2012 |
20120095439 | IMPLANTABLE THERAPEUTIC DEVICE - A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient. | 04-19-2012 |
20130165860 | FLUID EXCHANGE APPARATUS AND METHODS - An injector apparatus comprises an elongate structure having one or more openings positionable near a penetrable barrier of an implantable device so as to receive fluid of the implantable device. The apparatus comprises a needle and a sheath extending over at least a portion of the needle. The elongate structure may comprise a distal tip to penetrate tissue and the penetrable barrier, and a distal opening near the tip to release therapeutic fluid into the implantable chamber. In many embodiments the distal tip, the distal opening, and the plurality of openings are separated from a stop that engages a tissue of the patient and limit penetration depth such that the distal opening and the plurality of openings are located along an axis of the implantable device to increase an efficiency of the exchange. | 06-27-2013 |
20130204209 | Posterior Segment Drug Delivery - A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side. | 08-08-2013 |
20130274691 | COMBINED DRUG DELIVERY METHODS AND APPARATUS - Methods and apparatus provide treatment with a first therapeutic agent and a second therapeutic agent for an extended time. The first therapeutic agent may comprise a VEGF inhibitor and the second therapeutic agent may comprise an antiinflammatory, such as a non-steroidal anti-inflammatory, for example a cyclooxygenase inhibitor. One or more of the first therapeutic agent or the second therapeutic agent can be injected into the eye, for example injected into a therapeutic device implanted into the eye to release the injected therapeutic agent for an extended time. | 10-17-2013 |
20130274692 | SUBCONJUCTIVAL IMPLANT FOR POSTERIOR SEGMENT DRUG DELIVERY - A therapeutic device can be configured to place the reservoir substantially between the conjunctiva and the scleral such that the size of the reservoir can be increased and the size of the scleral penetration decreased so as to decrease invasiveness. The device may comprise a substantially constant reservoir volume and drug release mechanism, in which the volume of the reservoir and mechanism are tuned to receive a quantity of therapeutic agent with a volume of injected formulation and release the therapeutic agent for an extended time with a release rate profile. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent, and a plurality of interconnecting channels can extend from the first side to the second side. | 10-17-2013 |
20130324918 | INJECTOR APPARATUS AND METHOD FOR DRUG DELIVERY - Methods and apparatus provide a therapeutic fluid to devices implanted in the body, for example to containers of devices implanted in the eye of a patient. The methods and apparatus may comprise an injector to increase an amount of therapeutic agent injected into the device implanted in the eye, or a structure to receive the therapeutic fluid within the device implanted in the eye, or combinations thereof. The device implanted in the eye may comprise a reservoir chamber having a fluid with a density different than the therapeutic fluid, and the apparatus can be adapted to at least partially separate the implanted device fluid from therapeutic fluid within the reservoir chamber to increase and amount of therapeutic fluid placed in the reservoir chamber. | 12-05-2013 |
20130324942 | IMPLANTABLE THERAPEUTIC DEVICE - A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the 188 second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient. | 12-05-2013 |
20140031769 | THERAPEUTIC AGENT FORMULATIONS FOR IMPLANTED DEVICES - An injectable formulation of therapeutic agent may comprise the therapeutic agent and a stabilizer such that a substantial portion of the stabilizer remains in the therapeutic device to stabilize the therapeutic agent when the therapeutic agent is released from the therapeutic device. The injectable formulation may comprise one or more of binding agent particles or erodible material particles, such that the formulation can be injected into the therapeutic device. The binding agent particles can bind reversibly to the therapeutic agent so as to modulate release of the therapeutic agent, and the erodible material particles can generate protons of an acid so as to increase stability of the therapeutic agent and may modulate release of the therapeutic agent. The therapeutic agent can be combined with one or more of the stabilizer, the binding agent particles or the erodible particles to increase stability of the therapeutic agent and may modulate release. | 01-30-2014 |
20140033800 | METHODS AND APPARATUS TO DETERMINE DIFFUSION PROPERTIES OF POROUS STRUCTURES FOR DRUG DELIVERY - Disclosed herein are improved therapeutic devices and methods and improved porous structures and measurement apparatus for use with therapeutic devices. In many embodiments, a porous structure is measured based on diffusion of the gas through the porous structure. The gas measurement may comprise an amount of gas measured to determine a resistance of the porous structure to diffusion. The diffusion of the gas through the porous structure can be used to determine release of a therapeutic agent through the porous structure, such that targeted amounts of therapeutic agent can be released for extended times and such that therapeutic device reservoir volume and porous frit structure can be tuned to release the therapeutic agent for an extended time above a target amount for the extended time. | 02-06-2014 |
20140121609 | IMPLANTABLE THERAPEUTIC DEVICE - A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient. | 05-01-2014 |
20140221941 | DIAGNOSTIC METHODS AND APPARATUS - An apparatus to treat a patient comprises a container to receive fluid of a device implanted in the eye. The fluid of the device can be analyzed to determine a component of the vitreous humor of the eye. | 08-07-2014 |
20140358125 | SMALL MOLECULE DELIVERY WITH IMPLANTABLE THERAPEUTIC DEVICE - A therapeutic device that can release a therapeutic agent comprising a porous structure coupled to a container comprising a reservoir. The reservoir can comprise a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in a patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device may comprise a penetrable barrier to inject therapeutic agent into the device when implanted in the patient. | 12-04-2014 |
Patent application number | Description | Published |
20100255061 | Posterior Segment Drug Delivery - A therapeutic device to release a therapeutic agent comprises a porous structure coupled to a container comprising a reservoir. The reservoir comprises a volume sized to release therapeutic amounts of the therapeutic agent for an extended time when coupled to the porous structure and implanted in the patient. The porous structure may comprise a first side coupled to the reservoir and a second side to couple to the patient to release the therapeutic agent. A plurality of interconnecting channels can extend from the first side to the second side so as to connect a first a plurality of openings on the first side with a second plurality of openings on the second side. Each of the openings on the first side can be connected to each of the openings on the second side with the plurality of interconnecting channels, such that the rate of release of the therapeutic agent can be substantially maintained when one or more of the openings is blocked, for example with particles, cells, bacteria or tissue when the device is implanted for an extended time. The length of the channels extending from the first side to the second side may comprise an effective length greater than a distance across the porous structure from the first side to the second side. The therapeutic device many comprise an expandable retention structure and an expandable reservoir, such that the device can be delivered from a lumen of a delivery device and expand when positioned in the patient. The therapeutic device may comprises a penetrable barrier to inject therapeutic agent into the device when implanted in the patient. | 10-07-2010 |
20110200599 | SUSTAINED DRUG DELIVERY SYSTEM - A drug composition comprising a charged moiety coupled to a therapeutic compound is disclosed. The charged moiety is configured to interact with at least one type of component of opposite charge in a biological tissue to create an in situ depot for prolonged drug delivery. The biological tissue may be eye tissue or any tissue containing charged components. Further, a method of treating the human body is disclosed. The method is for introducing into a human body a drug composition comprising a charged moiety coupled to a therapeutic compound. Introduction may be through injection. A method of manufacturing a drug composition comprising a charged moiety coupled to a therapeutic compound is also disclosed. | 08-18-2011 |
20120101260 | SUSTAINED DRUG DELIVERY SYSTEM - A drug composition comprising a charged moiety coupled to a therapeutic compound is disclosed. The charged moiety is configured to interact with at least one type of component of opposite charge in a biological tissue to create an in situ depot for prolonged drug delivery. The biological tissue may be eye tissue or any tissue containing charged components. | 04-26-2012 |
20140248296 | SUSTAINED DRUG DELIVERY SYSTEM - A drug composition comprising a charged moiety coupled to a therapeutic compound is disclosed. The charged moiety is configured to interact with at least one type of component of opposite charge in a biological tissue to create an in situ depot for prolonged drug delivery. The biological tissue may be eye tissue or any tissue containing charged components. | 09-04-2014 |
20140276482 | Systems for Sustained Intraocular Delivery of Low Solubility Compounds from a Port Delivery System Implant - Therapeutic agent delivery formulations for the sustained release of therapeutic agents from a Port Delivery System (PDS) implant is described in this application. | 09-18-2014 |